salt thereof.

(16) The pharmaceutical composition according to any one of (1) to (15), which does not comprise sorbic acid.

(17) The pharmaceutical composition according to any one of (1) to (16), which is filled into a container made of polyethylene.

(18) Use of the pharmaceutical composition according to any one of (1) to (17), in the manufacture of a medicament for prevention or treatment of glaucoma or ocular hypertension, or for reduction of intraocular pressure.

(19) A method for stabilizing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof by allowing a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof to comprise edetic acid or a salt thereof.

(20) A method for improving preservative effectiveness of a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof by allowing the pharmaceutical composition to comprise edetic acid or a salt thereof.

The respective structures of the above-mentioned (1) to (20) can be combined by optionally selecting two or more structures therefrom.

Effects of the Invention

According to the present invention, it is possible to

ylsulfonyl)aminomethyl}pyridin-2-ylamino)isopropyl acetate or a salt thereof.

15. The pharmaceutical composition according to any one of claims 1 to 14, which further comprises boric acid or a salt thereof, citric acid or a salt thereof, or acetic acid or a salt thereof.

16. The pharmaceutical composition according to any one of claims 1 to 15, which does not comprise sorbic acid.

17. The pharmaceutical composition according to any one of claims 1 to 16, which is filled into a container made of polyethylene.

18. Use of the pharmaceutical composition according to any one of claims 1 to 17, in the manufacture of a medicament for prevention or treatment of glaucoma or ocular hypertension, or for reduction of intraocular pressure.

19. A method for stabilizing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof by allowing a pharmaceutical composition comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof to comprise edetic acid or a salt thereof.